Related Experiment Video
Updated: Mar 22, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immune based therapy for melanoma
Robert Ancuceanu1, Monica Neagu
1University of Medicine and Pharmacy "Carol Davila", Bucharest, Faculty of Pharmacy, Bucharest, Romania.
Abstract:
A few years ago therapeutic options in advanced melanoma were very limited and the prognosis was somber. Although recent progresses are far from providing a cure for advanced melanoma, yet these have kindled new hopes and searching for a cure does not seem unreasonable. Seven new medicines have been authorized in various regions of the world in the recent past in the therapy of advanced melanoma, over half of them acting by mechanisms involving the immune system of the host. The anti-CTLA-4 (cytotoxic T lymphocyte associated protein-4) ipilimumab has been followed by anti-PD1 (programmed death1) inhibitors, more effective and safer. Very recently, the first oncolytic immunotherapy, talimogene laherparepvec (T-VEC) has been authorized for placing on the market and a variety of combinations of the new therapies are currently being evaluated or considered. Besides, a plethora of other molecules and approaches, especially monoclonal antibodies, are in the preliminary phases of clinical investigation and are likely to bring new benefits for the treatment of this potentially fatal form of cancer.
Insights
Recent advancements in advanced melanoma treatment offer new hope. Several immunotherapies, including ipilimumab and anti-PD1 inhibitors, have been approved, with more therapies in development.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced melanoma previously had limited treatment options and a poor prognosis.
- Recent therapeutic progress has significantly improved outcomes and outlook for patients.
Purpose of the Study:
- To review recent advancements in the treatment of advanced melanoma.
- To highlight novel therapeutic agents and their mechanisms of action.
Main Methods:
- Review of recently authorized therapies for advanced melanoma.
- Discussion of immunotherapeutic agents such as ipilimumab and anti-PD1 inhibitors.
- Inclusion of oncolytic immunotherapy (talimogene laherparepvec) and combination strategies.
Main Results:
- Seven new medicines have been approved globally for advanced melanoma treatment.
- Over half of these new therapies leverage the host's immune system.
- Emerging therapies include anti-CTLA-4, anti-PD1 inhibitors, and oncolytic viruses.
Conclusions:
- Current therapeutic options for advanced melanoma have expanded significantly.
- Immunotherapy and combination approaches represent the forefront of treatment innovation.
- Ongoing research into novel molecules and strategies promises further benefits for patients.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...